Cybin Corp. Archives - Page 3 of 3

WednesdayJul 29, 2020 2:05 pm

QualityStocksNewsBreaks – Cybin Corp. to Deliver Psychedelic Medicines Targeting Conditions Failed by Big Pharma

Cybin Corp. appears set for opportunity as new data increasingly finds promise in psychedelic medicines. As big pharma has failed to bring groundbreaking drug innovations into the mental-health space, psilocybin — the main compound of pharmaceutical psychedelic products — stands out, having shown positive results for the treatment of anxiety, depression, addiction, and eating and other disorders. A recent article discussing the company’s positioning reads, “Cybin is potentially poised to be the first company to develop psilocybin-based medicine designed to target major depressive disorders. Currently involved in structuring a clinical study that will be conducted through an academic partner in…

FridayJul 24, 2020 1:24 pm

Cybin Corp. Potentially Poised to be First Company Bringing Psychedelic Medicine to Treat Major Depressive Disorder

Psychedelics have shown positive results for treatment of mental health conditions including anxiety, depression, PTSD, addiction, eating disorders, ADHD Big pharma failed to bring drug innovations in mental health space; psychedelics may satisfy vast unmet need With secured delivery mechanisms and manufacturing contract in hand, Cybin appears well positioned to capitalize on growing market trend As big pharma has failed to bring groundbreaking drug innovations into the mental health space, new data increasingly shows that psychedelics may close this gap, creating an entirely new market of safe and effective psychedelics medicines (http://ibn.fm/M6gla). Cybin Corp., a leading Canada-based, life-sciences company, is focused…

WednesdayJul 22, 2020 12:49 pm

QualityStocksNewsBreaks – Cybin Corp. Advancing ‘Fungi-Derived’ Products Amid Mushrooming Interest in Psychedelics

Cybin Corp., a Canada-based, life-sciences company focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market, looks to be in the right place at the right time. A mushrooming interest fuels this sector in an era where psychedelics, once a taboo substance, are being viewed in a powerful new light. A recent article discussing the company and its focus in this emerging space reads, “Cybin is committed to its mission of bringing ‘fungi-derived psychedelic and medicinal products into the world that may potentially drive the next discovery phase of life-changing medications to treat mental illness…

TuesdayJul 14, 2020 12:44 pm

Cybin Corp. Emerging as Leader in Growing Psychedelics Space

Clinical studies show serotonergic psychedelics may be effective in treating anxiety, depression, addiction and more Interest in serotonergic psychedelics has dramatically increased within last decade Cybin Corp. is focused on furthering research, development of psilocybin-based medications through Serenity Life Sciences Inc. For decades seen as a taboo substance, psychedelics today are being viewed in a powerful new light. This significant societal switch is based, at least in part, on credible clinical studies, which have shown that serotonergic psychedelics may be effective in treating anxiety, depression, addiction and even cancer (http://ibn.fm/mSzY5). Cybin Corp., a Canada-based life sciences company focused on the pharmaceutical…

TuesdayJul 14, 2020 11:23 am

QualityStocksNewsBreaks – Why Cybin Corp. Is ‘One to Watch’

Cybin Corp. is Canada's premier mushroom life-sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi. A recent article discussing the company reads, “In particular, Cybin aims to further build upon and expand its intellectual property (‘IP’) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.” To view the full article, visit http://ibn.fm/o1exG About Cybin Cybin is a…

TuesdayJul 07, 2020 3:03 pm

Cybin Corp. is “One to Watch”

Cybin is a leading Canada-based mushroom life sciences company focused on psychedelic medicines and nutraceutical products The company has two operating divisions – Serenity Life Sciences (psychedelic pharmaceutical products) and Natures Journey Inc. (medicinal nutraceutical products) Members of Cybin’s experienced management team have collectively run multiple clinical trials and helped facilitate over $1 billion in pharmaceutical sales The company recently announced a strategic partnership with the Toronto Centre for Psychedelic Science Cybin is currently marketing a range of fungi-based supplements under its Journey brand aimed at breaking into the global non-psychedelic legal supplement market, which is valued at $25 billion…

TuesdayJul 07, 2020 1:33 pm

QualityStocksNewsBreaks – Cybin Corp. and IntelGenx Corp. to Collaborate in Development of Fast-Acting Psilocybin Film

Cybin Corp., Canada's premier mushroom life sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi, today announced its entry into a feasibility agreement with IntelGenx Corp. (OTCQB: IGXT) (TSX-V:IGX) for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin, subject to receipt of all necessary regulatory approvals. “We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film,” Cybin’s Chief Medical Officer, Dr. Jukka Karjalainen, stated in the news release. “Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver,…

WednesdayJul 01, 2020 1:09 pm

QualityStocksNewsBreaks – Cybin Corp. Announces Reverse Take-Over and Up-To $21M Concurrent Private Placement

Cybin Corp., a mushroom life sciences company focused on psychedelic medicines and nutraceutical products, on Monday announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly-owned subsidiary of Clarmin. According to the update, completion of the transactions contemplated in the agreement will result in the reverse takeover of Clarmin by Cybin (the “Proposed Transaction”). In connection with the Proposed Transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (“Stifel GMP”)…

Site Search

Company Search

Tag: Cybin Corp.